Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

Dr Reddy's Laboratories

It has collaborated with MerckBSE 1.25 % Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). It indicated that this would see the quantitative visibility over the long run.

It launched a prostrate cancer drug, PamorelinO LA, in India. The company has signed an exclusive marketing and sales agreement with Debiopharma Group of Switzerland. Dr Reddy's will import the drug in bulk and supply the same to urologists and oncologists in India.

On the biosimilars front, the company has alliance with the GSK specifically for the Emerging markets. The Biosimilars, which were in pipeline, would be launched in the Indian market (already launched 4 products) and then in the emerging markets. However, it would take a few years to become a significant contribution to the sales.

The company launched the generic version of sildenafil tablets in the US market. It launched the drug following approval by the USFDA for its abbreviated new drug application for sildenafil tablets.

The company has entered into a partnership with the Cellceutix Corporation based in Massachusetts, a clinical stage biopharmaceutical company. The partnership is for the purpose of manufacturing Prurisol, a new drug candidate for treating psoriasis.